Public Policy Resources

ACS CAN led a support letter with 195 organizations supporting the passage of S.4440, the Clinical Trial Modernization Act, a bill that would help remove financial barriers to clinical trial participation. 

ACS and ACS CAN have submitted joint comments opposing a proposed rule from OMB that would dramatically change how federal grants are made and managed.  The proposal would require political review of grants, make grants easy to cancel, and would erect significant barriers to DEI-related research.

La Red de Acción Contra el Cáncer de la Sociedad Americana Contra el Cáncer (ACS CAN) insta al Congreso a financiar el Programa Nacional de Registros de Cáncer (NPCR) de los Centros para el Control y la Prevención de Enfermedades (CDC) con $63.4 millones de dólares en el año fiscal 2027.

NIH plays a critical role in the cancer research ecosystem, driving basic discoveries, supporting research infrastructure, and funding critical research that would not be funded by any other entity. ACS CAN has provided recommendations to NIH as it develops its next 5-year strategic plan. 

Increased investment at the National Institutes of Health (NIH), the National Cancer Institute (NCI), and level funding for Advanced Research Projects for Health (ARPA-H), in the fight against cancer year over year have been key to reducing the nation’s cancer mortality rate by 34% since 1991. To

Our latest Survivor Views survey underscores the critical role of evidence-based vaccinations in promoting public health and protecting communities impacted by cancer. Cancer patients and survivors overwhelmingly agree on the importance of community immunization, oppose limits to vaccine access, and support school entry requirements. In addition, the survey finds strong support for investment in the oncology potential of vaccines.

ACS CAN submitted a response to the December 2025 Request for Information on Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care. 

Twenty five groups joined to ask the HHS Office of Inspector General (OIG) to create a safe harbor from the Anti-Kickback Statute (AKS) allowing sponsors to financially support participants in cancer clinical trials. 

Our latest survey finds 80% of cancer patients and survivors agree that industries making FDA-regulated products should provide some of the cost of FDA’s public health oversight. The survey also reveals hesitency toward the increased use of AI, mirroring the sentiment of the American public. Cancer patients and survivors offer tempered support for the use of AI in FDA product reviews if funding cuts extend review times, with a plurality undecided on whether they support or oppose it.